

---

**For immediate release**

## **ConjuChem Announces Changes to the Board of Directors**

**MONTREAL, Canada, May 28, 2008** – ConjuChem Biotechnologies Inc. (TSX:CJB) today announced two changes in the composition of its Board of Directors.

Leaving the ConjuChem Board is Dr. Philippe Pouletty, who has served as a Director since 1997. Dr. Pouletty, General Partner of Truffle Capital (Paris, France) and chairman of France Biotech, the French biotechnology industry association, was the founder of RedCell Inc., the predecessor company to ConjuChem.

Joining the ConjuChem Board is William K. Heiden, currently President and CEO of Elixir Pharmaceuticals, Inc. (Cambridge, MA). Mr. Heiden was previously the President and COO of Praecis, which was subsequently purchased by GlaxoSmithKline, and has held numerous management positions at Schering-Plough Corporation including Vice President of Schering's Oncology/Biotech Division. Mr. Heiden holds an M.B.A. from Cornell University's Johnson Graduate School of Management, an M.A. from the University of Louvain and a B.S. from the University of Florida.

Regarding the changes, Chairman of the Board Jacques Lapointe commented, “The Board would like to thank Dr. Pouletty for his many years of service and we look forward to working with Mr. Heiden.”

### **About ConjuChem Biotechnologies**

ConjuChem Biotechnologies, developer of next generation medicines from therapeutic peptides, is creating long-acting compounds based on its bioconjugation platform technologies. When applied to peptides, the Company's systemic DAC<sup>™</sup> and PC-DAC<sup>™</sup> technologies enable the creation of new drugs with significantly enhanced therapeutic properties as compared to the original peptide. Detailed descriptions of the Company can be viewed on the Company's website [www.conjuchem.com](http://www.conjuchem.com).

### **For more information, please contact:**

Lennie Ryer, CA  
Vice President, Finance & CFO  
ConjuChem Biotechnologies Inc.  
514-844-5558, ext. 224  
[ryer@conjuchem.com](mailto:ryer@conjuchem.com)

James Smith  
Investor Relations  
416.815.0700, ext. 229  
[jsmith@equicomgroup.com](mailto:jsmith@equicomgroup.com)